Images List Premium Download Classic

Immune Diseases

Immune Diseases-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
University Of Connecticut
October 12, 2017 - N°20170290864

The disclosure provided herein relates generally to mesenchymal-like stem cells “hes-t-misc” or “t-msc” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hes-t-msc or t-msc, t-msc ...
Rna polymerase i inhibitors and uses thereof
Tel Hashomer Medical Research Infrastructure And Services, Ltd.
October 12, 2017 - N°20170290842

Provided are novel compounds which are capable of inhibiting an activity of rna polymerase i, and uses thereof in treating diseases or disorders modulated by rna polymerase i, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.
Immune system modulation for prophylaxis and treatment of diseases and disorders
Marpe Holdings, Llc
October 05, 2017 - N°20170283460

The invention is directed to biological response modifiers (brm) which may contain one or more compounds, and to methods for enhancement of an immune system with brms of the invention including augmenting a specific immune response either prophylactically or for treatment, as an adjuvant or vaccine when coupled with a pathogenic antigen, and for boosting an immune system generally. The ...
Immune Diseases Patent Pack
Download 177+ patent application PDFs
Immune Diseases Patent Applications
Download 177+ Immune Diseases-related PDFs
For professional research & prior art discovery
inventor
  • 177+ full patent PDF documents of Immune Diseases-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Bruton's tyrosine kinase inhibitors
Pfizer Inc.
October 05, 2017 - N°20170283393

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseeases or conditions, heteroimmune diseases or conditions, cancer, ...
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
Zhejiang Dtrm Biopharma Co. Ltd.
October 05, 2017 - N°20170281810

Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of btk, mtor kinase, and bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.
Cholix toxin-derived fusion moelcules for oral delivery of biologically active cargo
Applied Molecular Transport, Llc
October 05, 2017 - N°20170281736

The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e. G., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form ...
Immune Diseases Patent Pack
Download 177+ patent application PDFs
Immune Diseases Patent Applications
Download 177+ Immune Diseases-related PDFs
For professional research & prior art discovery
inventor
  • 177+ full patent PDF documents of Immune Diseases-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Bioassay for the early detection of autoimmune diseases
Ayuvis Research Llc
September 28, 2017 - N°20170276674

Provided are methods for aiding in diagnosing autoimmune diseases in a mammal, comprising contacting a biological sample that is not a tear sample from the mammal with an antibody that specifically binds to a first polypeptide selected from the group ctss, ctsh, ctsr, ctsw, ctsz, ifng, il-6ra, il-10, il-10ra, il-15, tnfa, apo-f, or lcn-2 or a second polypeptide ...
Benzazepine sulfonamide compounds
Ayuvis Research Llc
September 28, 2017 - N°20170275253

Wherein r4 or r5 is —so2—nr7r8 and r1 to r8 and y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft ...
Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof
The Regents Of The University Of California
September 28, 2017 - N°20170274059

The invention provides a composition, and method of use thereof, comprising self-antigen displaying nanoparticles to target auto-reactive immune components for treating and/or preventing the autoimmune diseases associated therewith. The nanoparticles can also be loaded with cytotoxic drugs for targeted cell killing or with immune-tolerizing compounds to normalize the immune regulation.
Therapeutic uses of cd137pos regulatory t cells in treating autoimmune diseases
University Of Cincinnati
September 28, 2017 - N°20170274043

A method for treating or preventing a t-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells. Also provided are pharmaceutical compositions for treating or preventing t-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble cd137 or ...
Pharmaceutical compositions comprising soluble cd137
University Of Cincinnati
September 28, 2017 - N°20170274042

A method for treating or preventing a t-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells. Also provided are pharmaceutical compositions for treating or preventing t-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble cd137 or ...
Methods for treating gi syndrome and graft versus host disease
Board Of Regents, The University Of Texas System
September 28, 2017 - N°20170273987

We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic t lymphocyte (ctls)-induced killing and by damage to endothelial microvasculture, including radiation-induced gi syndrome, graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or ...
Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
Board Of Regents, The University Of Texas System
September 28, 2017 - N°20170273958

Disclosed herein are methods for counteracting age-related decrease in gene expression or treating age-related diseases, for example cancers and autoimmune diseases, caused by decreased expression levels of a gene associated with the apoptosis pathway, using a nitroxide. Further disclosed are methods for treating a human subject in need of an increased expression level of a gene associated with the apoptosis ...
Immune Diseases Patent Pack
Download 177+ patent application PDFs
Immune Diseases Patent Applications
Download 177+ Immune Diseases-related PDFs
For professional research & prior art discovery
inventor
  • 177+ full patent PDF documents of Immune Diseases-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
Dana-farber Cancer Institute, Inc.
September 21, 2017 - N°20170269076

Methods for diagnosing and prognosing autoimmune diseases and t cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (opn-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor bcl6, which is involved in t cell activation/differentiation. Other aspects of the disclosure provide methods for enhancing adoptive t cell transfer.
Indole compounds and pharmaceutical use thereof
Dana-farber Cancer Institute, Inc.
September 21, 2017 - N°20170267662

Wherein each symbol is as described in the specification. The invention also provides a method for the treatment or prophylaxis of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection or the like in a mammal by administering the compound or pharmaceutically acceptable salt thereof or solvate thereof to the mammal.
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
Immunomedics, Inc.
September 21, 2017 - N°20170266281

Disclosed are methods, compositions and uses of concentrated formulations of anti-cd74 antibody, of use for treating autoimmune diseases. In a specific non-limiting embodiment, the autoimmune disease is systemic lupus erythematosus (sle). In a preferred embodiment, the anti-cd74 antibody is milatuzumab (immu-115). The antibody is administered subcutaneously, preferably at a dosage of 250 mg once a week for four weeks. The subcutaneous ...
Method and kit for the predictive prognosis of responsiveness to treatments of autoimmune diseases
Universita' Degli Studi Di Roma "la Sapienza"
September 14, 2017 - N°20170261505

The present invention relates to the use of one or more mhc class i molecules dextramers (dextramers®) associated with peptides corresponding to apoptotic epitopes of human cd8+ t cells for the predictive prognosis of responsiveness or non-responsiveness to treatments and/or for monitoring the therapeutic effectiveness of treatments with biological medicaments that block and/or inhibit tnf, and/or ...
Indole carboxamide compounds
Universita' Degli Studi Di Roma "la Sapienza"
September 14, 2017 - N°20170260160

Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic ...
Treatments for autoimmune disease
The Provost, Fellows, Foundation Scholars, And The Other Members Of Board,of The College Of The Holy
September 14, 2017 - N°20170258797

The invention relates to a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis. In a further embodiment of the invention there is provided a molecule capable of acting as substrate for the queuine-insertase enzyme complex and where said molecule is not a substrate for hypoxanthine-guanine phosphoribosyltransferase and said molecule has the effect of lowering interferon gamma, for ...
Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Pharmacyclics Llc
September 14, 2017 - N°20170258729

Described herein are pharmaceutical formulations of bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, ...
Method for the detection of antigen presentation
Deutsches Krebsforschungszentrum Stiftung Des öffentlichen Rechts
September 07, 2017 - N°20170254803

The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (mhc) class i or ii. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule. The binding agents of the invention are coupled to proximity probes which ...
Loading